Published on 3 Jan 2022 on Entrpreneur
Lexicon (LXRX) Submits NDA to the FDA for Cardiovascular Drug
Lexicon Pharmaceuticals, Inc. LXRX announced the submission of a new drug application (NDA) to the...
NASDAQ.LXRX price evolution
Want to become a better investor?
Start tracking your investments with Statfolio
Sign up for free